Almut G Winterstein

Almut G Winterstein, RPh, PhD, FISPE

Distinguished Professor & Chair In POP, Director For CoDES, Director For Consortium For Medical Marijuana Clinical Outcomes Research

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 273-6258
Business Email: almut@ufl.edu

About Almut G Winterstein

Almut Winterstein received her pharmacy degree from Friedrich Wilhelm University in Bonn, Germany and her PhD in Pharmacoepidemiology from the Humboldt University in Berlin, Germany. She holds the position of distinguished professor in the Department of Pharmaceutical Outcomes and Policy at the College of Pharmacy and is the founding Director of the Center for Drug Evaluation and Safety, both at the University of Florida. She has an affiliate appointment in the Department of Epidemiology at the Colleges of Medicine and Public Health and Health Professions. In 2017, she was named the Dr. Robert and Barbara Crisafi Chair for Medication Safety in recognition of her research on drug safety and on devising ways to improve medication use. Since 2019 she also serves as director of the Consortium for Medical Marijuana Clinical Outcomes Research, a State of Florida-funded multi-university group devoted to enhance our understanding of the risk-benefit of medical uses of cannabis.

Since joining the University of Florida in 2000, Winterstein has served as principal investigator on more than 25 extramurally funded grants and contracts and published more than 400 manuscripts and conference abstracts. Her research interests have centered on the post-marketing evaluation of drugs in pediatrics and perinatal care, infectious disease and psychiatry and the evaluation and improvement of quality surrounding medication use using real-world data. As expert in drug safety, she has chaired the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee from 2012-2018. Recognizing her contributions in pharmacoepidemiology, Dr. Winterstein was inducted as a fellow of the International Society of Pharmacoepidemiology in 2013 and currently serves as president of the society. Before she became department chair in 2016, Dr. Winterstein served as graduate program director in her department. She has chaired more than two dizen PhD committees and was awarded the UF-wide Dissertation Advisor/Mentoring award for her excellence in graduate training. In 2022 she was inducted in the Academy of Science, Engineering and Medicine of Florida.

Related Links:
Additional Positions:
Director
2019 – Current · Consortium for Medical Marijuana Clinical Outcomes Research
Director
2019 – Current · Center for Drug Evaluation and Safety (CoDES)

Teaching Profile

Courses Taught
2009-2021
PHA7980 Research for Doctoral Dissertation
2009-2023
PHA7979 Advanced Research
2011,2019-2023
PHA6940 Supervised Teaching
2010-2011,2014-2023
PHA6717 Measurement in Pharmaceutical Outcomes and Policy Research
2018
PHA5876C Pt Care 8 Complex Pts
2018
PHA5784C Pt Care 4: GI and Renal
2010-2012,2017-2021,2021
PHA6971 Research for Master’s Thesis
2017
PHA5226C Pt Safety and Quality
2017
PHC7980 Research for Doctoral Dissertation
2013-2015,2017
PHA6266 Introduction to Pharmaceutical Outcomes and Policy II
2015,2021-2022
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2013-2015
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2010-2015
PHA6279 Pharmaceutical Outcomes and Policy Seminar
2006,2011-2013,2013-2014
PHA5901 Res Ph Outcome and Plcy
2006-2014
PHA5226 Evidence-Base Pharmcy
2014,2021-2022
PHA6938 Research Seminar
2009-2013
PHA6796 Study Design in Pharmaceutical Outcomes & Policy Research
2013
PHA5267 Crit Appr Pharmacoeco
2013
PHA5907 Research in Phar Prac
2010-2017,2019-2021
PHA6936 Advanced Topics in Pharmaceutical Sciences
2010-2021
PHA6937 Topics in Pharmaceutical Administration
2010-2018,2020-2023
PHA6910 Supervised Research
2010-2012,2014-2022,2020-2023
PHA6935 Selected Topics in Pharmacy
Teaching Philosophy
I have provided my teaching and mentoring philosophy above. The following summarizes the focus of my teaching. Brief statement of the context of my teaching My teaching is closely tied to my research program, and accordingly aimed at developing scientists who use real-world data to improve drug therapy outcomes and improve public health. In our professional PharmD curriculum, I have developed and coordinated courses that have focused on knowledge and skills aimed at improving patient outcomes through population-based approaches to patient care. The core of this has been the development and coordination of PHA 5226, Evidence-based Pharmacy, a 4-credit hour mandatory course for PharmD students in their 3rd professional year, which I have taught for a decade. Innovative in the course design has been the blend of critical appraisal of drug safety and effectiveness studies and the assessment and improvement of quality of clinical care. Both, research studies and quality improvement use population-based approaches to evaluate the effect of a particular intervention and both require understanding of measurement, design and analytical approaches. Students learn to identify and evaluate primary literature for a given clinical problem and, following the paradigms of evidence-based medicine, to evaluate whether evidence is consequently implemented in their own practice and leads to the desired outcomes. I am still contributing lectures of similar content, which is now coordinated by my faculty within three separate courses (Evidence-based Practice, Pharmacoepidemiology and Drug Safety, and Quality and Patient Safety). Further expansion of this content towards enhanced data analytics skills in conjunction with UF’s artificial intelligence initiative is critical to equip the new generation of clinicians with the ability to use the rapidly expanding access to healthcare data to guide, evaluate, and improve care. Instruction in graduate education. Pharmacoepidemiology aims to use population-based data to make causal inference about drug effects in real-world populations. As such it complements clinical trials, but comes with unique challenges in study, design, measurement and analysis, because study populations are not randomized, measurements are not protocol-based, and treatments are not implemented following strict protocols. Analyses of real-world data are therefore only as valid as investigators’ recognition and management of biases inherent in such data. My teaching in our graduate curriculum, as well as via my advisory role, is grounded in principles of refutationism, where trainees are challenged to identify and resolve potential flaws in their study design and measurement and refute their own findings. The central component of my teaching is PHA 6717, Measurement in Pharmaceutical Outcomes & Policy, a required course in the second year of our residential MS and PhD curriculum, which I have taught since 2008. This course introduces common real-world data sources, discusses pitfalls in measurement of exposure, covariates and outcomes, related effects on study validity and bias and methods to address such biases. My most cited paper (>1300 citations) has originated from this course (AJHP 2008). Teaching-related improvement activities. Concordant with my growing administrative roles, improvement activities in teaching in the past ten years have focused on higher level change. For example, during the complete overhaul of our PharmD curriculum, I converted previous course content involving knowledge and skills in evidence-based medicine/population-based care into three new courses to allow broader spread throughout the curriculum. As graduate program director, I developed the curriculum for a specialty track in pharmacoepidemiology. This was informed by an international survey on related curricular content in peer programs, which I initiated as chair of the International Society of Pharmacoepidemiology (ISPE) academic council. Since 2011 I have regularly taught an introductory course in pharmacoepidemiology at the ISPE Midyear and Annual Meetings. I have designed and taught similar courses on development and design of drug evaluation and quality improvement studies for the American Society of Health-Systems Pharmacists and organized several annual summits on patient safety for the Florida Office of Rural Health.

Research Profile

My scholarly work has contributed to public health through three mechanisms: (a) by generating evidence on drug safety and effectiveness in real-world populations, (b) by evaluation of policy or programs that affect medication use and (c) by providing data-driven support of decision-making related to medication use (pharmaceutical data analytics/population-based care). While these three research areas may appear quite diverse, they are united by similar methodology that employs pharmacoepidemiologic methods on large data repositories for causal inference or prediction, and by the same goal to improve clinical outcomes through most effective and safe use of medications. As an epidemiologist, I have also contributed to the methodological advancement of my discipline in general and specifically, via development of new resources to enhance the assessment of medications in maternal and child health.

Contribution of new evidence on drug safety and effectiveness – Population-based observational studies of drug safety and effectiveness are critical when randomized trials are not feasible (e.g., due to ethical or logistical constraints such as for investigation of drug effects during pregnancy or of rare side effects requiring sample sizes that cannot be accomplished with prospective enrollment), or if treatment effects are modified by a range of parameters that require examination of heterogeneous populations. Pharmacoepidemiology focuses on the assessment of drug effects in real-world populations using large health databases and complements clinical trial evidence. Examples of such evaluations that I have led include assessments of rare safety outcomes such as the cardiovascular (Winterstein, BMJ 2012, journal impact factor [IF] 27.6, Altmetric score [AS]: 38) and suicidal risk of central nervous system stimulants in the treatment of attention-deficit/hyperactivity disorder (Linden, Pediatrics 2016, IF: 5.4, AS: 43), the effect of quinolone ear drops on tympanic membrane perforations (Alrwisan, 2017, IF: 9.1, AS: 528), and the effect of combinations of opioids with skeletal muscle relaxants on the risk for opioid overdose (Li, Clin Pharm Ther 2020, IF:7.3 AS: pending). I am currently funded by the FDA to evaluate the safety of gadolinium-enhanced MRI procedures during pregnancy on the risk for stillbirth and sudden infant death, which will inform regulatory decisions regarding warnings or restrictions on the use of gadolinium in pregnancy. I have also conducted a variety of effectiveness studies that looked at scenarios where indications were expanded in clinical practice without clinical trial evidence to support efficacy. Since 2019, I have served as the principal investigator of the state-funded Medical Marijuana Clinical Outcomes Consortium, which aims to develop a repository of linked marijuana dispensing and medical records, to evaluate both safety and effectiveness outcomes. Several of my safety and effectiveness studies have informed current treatment guidelines, including for example, work on treatment and risk of respiratory syncytial virus in infants, which has been included in the American Academy of Pediatrics Vaccination guidelines and my work on stimulant safety, which have been included in Canadian and American guidelines and several position statements. In recognition of my contribution to pharmacoepidemiologic research, I was inducted as fellow of the International Society of Pharmacoepidemiology in 2013.

Evaluation of policies and programs that affect medication use – With our understanding of drug effects consistently improving, appropriate and timely adoption and integration of such emerging information in clinical practice requires similar research support as the study of drug effects itself. Motivated by my long-standing work on the FDA Drug Safety and Risk Management Advisory Committee, I have developed great interest in the effectiveness of regulatory action aimed at affecting provider or patient behavior to mitigate drug risk and optimize patient outcomes. I collaborated with the FDA to evaluate educational efforts such as the quality of consumer medication information dispensed in retail pharmacies (Winterstein, JAMA Intern Med 2012, IF: 20.8, AS: not available). The most recent expansion of this stream of research unites my interest in risk mitigation strategies and perinatal drug safety in the evaluation of FDA’s efforts to reduce fetal exposure to teratogens. Our first paper found suboptimal effectiveness of FDA’s risk mitigation program for mycophenolate (Sarayani 2019, BMJ Qual Safety, IF: 7.2; AS: 11), pointing to the need for enhanced efforts to prevent fetal exposure. Finally, a whole body of work over the past decade has evaluated drug utilization pattern and etiologies for suboptimal and disparate care. Examples include studies on psychotropic medication use in pediatrics, such as my paper on psychotropic polypharmacy trajectories in young children (Winterstein, J Clin Psych 2017, IF: 5.5, AS: 30).

Population-based care and quality improvement in medication use – Data are powerful tools to guide quality improvement efforts both through assessments of clinical care for benchmarking purposes as well as by delivering real-time guidance to support clinician and patient decision-making in concrete clinical scenarios. Though no longer a practicing clinician, I consider my work to support population-based care my clinical practice. My first funding as faculty at UF, shortly after release of the sentinel Institute of Medicine Report on Medical Errors, was focused on the development of EHR-based tools to characterize and measure medication errors in hospitals (Kanjanarat, AJHP 2003; IF: 1.9 ; AS: 3, 348 citations). In parallel I began to support the UF Health pharmacy service and the hospital Medication Safety Committee with EHR-based evaluations of ongoing quality improvement efforts. My experience in quality assessment and improvement resulted in more than a decade of collaboration with the Health Service Advisory Group to support the Centers for Medicare and Medicaid (CMS) Quality Improvement programs. Responsible for the scientific development and validation, my team developed 14 performance measures that are endorsed by the National Quality Forum (NQF) and used in CMS reporting and pay-for-performance programs (see for example Winterstein, Medical Care 2020, IF: 3.1, AS: 5). More recently, with funding from the ASHP Research Foundation, my team developed automated scoring systems that predict hospitalized patients’ risk for 16 preventable adverse drug events (Winterstein, AJHP 2018, IF: 1.9, AS: 12). We received funding from the FDA Safe Use Initiative to implement our hypo- and hyperglycemia prediction algorithms, which dynamically score risk and post a prioritized list of patients for intervention. I am particularly excited about this ongoing work because it expands process-focused clinical decision support to a patient-centered approach that aims to capture the totality of risk factors that might cause a preventable adverse drug event.

Methodological contributions to pharmacoepidemiology – Central to my research program is the use of existing real-world data to inform medication use. Critical for the validity of such work is the validity of the underlying data sources, i.e., the data’s ability to support causal inferences by providing appropriate comparison groups with similar risk for the examined outcome, valid capture of drug exposure (over time) and determinants thereof and accurate capture of relevant outcomes. While cumbersome, assessment of data’s fit for purpose is critical to avoid bias and ought to be shared with the larger research community. If significant issues are discovered, methodological workarounds might be feasible (but require testing) or data needs to be enhanced, e.g., through additional linkages. Several of my scientific papers have focused on the development and validation of measures of outcomes or risk factors for application in pharmacoepidemiologic causal inference studies such as my work on misclassification of diabetogenic risk (Winterstein, PDS 2014, IF: 2.9 , AS: not available) I have also extensively worked on database linkages and variable cross-validation such as the development of algorithms to evaluate whether encounters reimbursed under capitated payment schemes are fully captured in claims data (Choi, PDS 2109, IF: 2.9, AS: 3). To enhance our foundation for pharmacoepidemiologic work in pregnancy, my group has established and validated mother and infant linkages within public and private insured administrative data (Knox, PDS 2019, IF: 2.9, AS: not available) and cross-linked these data to Vital Statistics records to build algorithms to estimate gestational age and time of conception. These algorithms facilitate accurate timing of in utero exposure to enhance our ability to evaluate teratogens such as exemplified on our recent evaluation of mycophenolate (Thai, PDS 2020, IF: 2.9, AS: 10), and are a central component of my ongoing collaboration with colleagues at Harvard on a large, FDA-funded study aimed at enhancing this methodology.

Areas of Interest
  • Patient Safety
  • Pharmacoepidemiology
  • Program evaluation
Open Researcher and Contributor ID (ORCID)

0000-0002-6518-5961

Publications

2022
CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
Journal of the American Heart Association. 11(4) [DOI] 10.1161/jaha.121.024159.
2022
Are novel glucose-lowering agents’ cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.
Diabetes, obesity & metabolism. 24(1):154-159 [DOI] 10.1111/dom.14540. [PMID] 34472689.
2022
Association of injury after prescription opioid initiation with risk for opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study
PLOS Medicine. 19(9) [DOI] 10.1371/journal.pmed.1004101. [PMID] 36136971.
2022
Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.
Diabetes care. 45(4):1007-1012 [DOI] 10.2337/dc21-1722. [PMID] 35349656.
2022
Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study
PLOS Medicine. 19(3) [DOI] 10.1371/journal.pmed.1003921. [PMID] 35231025.
2022
Concurrent Use of Prescription Opioids and Gabapentinoids in Older Adults
American Journal of Preventive Medicine. 62(4):519-528 [DOI] 10.1016/j.amepre.2021.08.024. [PMID] 34802816.
2022
Development of a Translational Exposure‐Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug Products
Clinical Pharmacology & Therapeutics. 112(4):909-916 [DOI] 10.1002/cpt.2690.
2022
Discontinuation of Long-Term Opioid Therapy in Patients With Versus Without Dementia
American Journal of Preventive Medicine. 62(2):270-274 [DOI] 10.1016/j.amepre.2021.07.020. [PMID] 34702606.
2022
Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group‐based multi‐trajectory models
Addiction. 117(7):1982-1997 [DOI] 10.1111/add.15857.
2022
Enhancing Quality Measurement With Clinical Information: A Use Case of Body Mass Index Change Among Children Taking Second Generation Antipsychotics
Academic Pediatrics. 22(3):S140-S149 [DOI] 10.1016/j.acap.2021.11.012. [PMID] 35339240.
2022
Evaluation of a Beta-Blocker-Edema-Loop Diuretic Prescribing Cascade: A Prescription Sequence Symmetry Analysis.
American journal of hypertension. 35(7):601-609 [DOI] 10.1093/ajh/hpac013. [PMID] 35106529.
2022
Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade.
Pharmacoepidemiology and drug safety. 31(1):72-81 [DOI] 10.1002/pds.5362. [PMID] 34553438.
2022
Generalizability and accuracy of IBM MarketScan health risk assessment instrument data for augmentation of commercial claims data.
Pharmacoepidemiology and drug safety. 31(1):100-104 [DOI] 10.1002/pds.5371. [PMID] 34657354.
2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Clinical pharmacology and therapeutics. 112(1):146-155 [DOI] 10.1002/cpt.2612. [PMID] 35429163.
2022
Perioperative Use of Gabapentinoids and Risk for Postoperative Long-Term Opioid Use in Older Adults Undergoing Total Knee or Hip Arthroplasty.
The Journal of arthroplasty. 37(11):2149-2157.e3 [DOI] 10.1016/j.arth.2022.05.018. [PMID] 35577053.
2022
Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies
American Journal of Obstetrics and Gynecology. 227(2):263.e1-263.e38 [DOI] 10.1016/j.ajog.2022.01.004.
2022
Proceedings of the 2022 Cannabis Clinical Outcomes Research Conference
Medical Cannabis and Cannabinoids. 138-141 [DOI] 10.1159/000527080.
2022
Quinolone Ear Drops and Achilles Tendon Rupture
Clinical Infectious Diseases. [DOI] 10.1093/cid/ciac709.
2022
Risk of fetal or neonatal death or neonatal intensive care unit admission associated with gadolinium magnetic resonance imaging exposure during pregnancy
American Journal of Obstetrics and Gynecology. [DOI] 10.1016/j.ajog.2022.10.005.
2022
Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case-control study.
PLoS medicine. 19(3) [DOI] 10.1371/journal.pmed.1003947. [PMID] 35290389.
2022
Triangulation of pharmacoepidemiology and laboratory science to tackle otic quinolone safety
Basic & Clinical Pharmacology & Toxicology. 130(S1):75-80 [DOI] 10.1111/bcpt.13668. [PMID] 34611995.
2022
Uncontrolled Extensions of Clinical Trials and the Use of External Controls-Scoping Opportunities and Methods.
Clinical pharmacology and therapeutics. 111(1):187-199 [DOI] 10.1002/cpt.2346. [PMID] 34165790.
2022
Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines.
European journal of pediatrics. 181(2):841-845 [DOI] 10.1007/s00431-021-04233-6. [PMID] 34365543.
2022
Watchful Waiting for Acute Otitis Media.
Pediatrics. 150(1) [DOI] 10.1542/peds.2021-055613. [PMID] 35726560.
2022
Where to begin? Thirty must-read papers for newcomers to pharmacoepidemiology.
Pharmacoepidemiology and drug safety. 31(2):257-259 [DOI] 10.1002/pds.5382. [PMID] 34738294.
2021
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019
Medical Cannabis and Cannabinoids. 4(1):21-42 [DOI] 10.1159/000515069. [PMID] 34676348.
2021
A Pharmacoepidemiologic Approach to Evaluate Real-world Effectiveness of Hormonal Contraceptives in the Presence of Drug-drug Interactions.
Epidemiology (Cambridge, Mass.). 32(2):268-276 [DOI] 10.1097/EDE.0000000000001302. [PMID] 33196560.
2021
Agreement of Minimum Data Set 3.0 depression and behavioral symptoms with clinical diagnosis in a nursing home.
Aging & mental health. 25(10):1897-1902 [DOI] 10.1080/13607863.2020.1758921. [PMID] 32447973.
2021
An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.
Research in social & administrative pharmacy : RSAP. 17(1):2012-2017 [DOI] 10.1016/j.sapharm.2020.04.031. [PMID] 32409150.
2021
Association of US Food and Drug Administration Removal of Indications for Use of Oral Quinolones With Prescribing Trends.
JAMA internal medicine. 181(6):808-816 [DOI] 10.1001/jamainternmed.2021.1154. [PMID] 33871571.
2021
Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization.
Journal of the Pediatric Infectious Diseases Society. 10(3):317-325 [DOI] 10.1093/jpids/piaa107. [PMID] 32978942.
2021
Clinical Conditions and Prescription Drug Utilization among Early Medical Marijuana Registrants in Florida
Journal of Psychoactive Drugs. 53(3):185-194 [DOI] 10.1080/02791072.2020.1864069.
2021
Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
Journal of diabetes and its complications. 35(9) [DOI] 10.1016/j.jdiacomp.2021.107972. [PMID] 34247911.
2021
Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network.
Genetics in medicine : official journal of the American College of Medical Genetics. 23(7):1185-1191 [DOI] 10.1038/s41436-021-01118-9. [PMID] 33782552.
2021
Global covid-19 vaccine rollout and safety surveillance-how to keep pace.
BMJ (Clinical research ed.). 373 [DOI] 10.1136/bmj.n1416. [PMID] 34144957.
2021
Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes.
Diabetes care. 44(6):1344-1352 [DOI] 10.2337/dc20-1794. [PMID] 33875487.
2021
Health-Related Quality of Life and Health Utilities of Mild, Moderate, and Severe Asthma: Evidence from the Medical Expenditure Panel Survey
Journal of Asthma and Allergy. Volume 14:929-941 [DOI] 10.2147/jaa.s316278.
2021
Introducing Commentary Series: “Evidence in Context”.
Medical cannabis and cannabinoids. 4(1):61-62 [DOI] 10.1159/000512684. [PMID] 34676350.
2021
Letter by Sarayani et al Regarding Article, “Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque”
Circulation. 143(25) [DOI] 10.1161/circulationaha.120.052678.
2021
Medication Use for ADHD and the Risk of Driving Citations and Crashes Among Teenage Drivers: A Population-Based Cohort Study.
Journal of attention disorders. 25(11):1511-1518 [DOI] 10.1177/1087054720915768. [PMID] 32338114.
2021
Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients?
European journal of clinical pharmacology. 77(9):1409-1417 [DOI] 10.1007/s00228-021-03121-0. [PMID] 33772627.
2021
Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.
Clinical pharmacology and therapeutics. 110(1):179-188 [DOI] 10.1002/cpt.2161. [PMID] 33428770.
2021
Practice Patterns and Training Needs Among Physicians Certifying Patients for Medical Marijuana in Florida.
Journal of primary care & community health. 12 [DOI] 10.1177/21501327211042790. [PMID] 34452585.
2021
Priorities for Medical Marijuana Research from the Perspective of Physicians, Dispensary Owners/Staff, and Patients: A Survey Study
Medical Cannabis and Cannabinoids. 4(2):107-113 [DOI] 10.1159/000518105. [PMID] 35224430.
2021
Proceedings of the 2021 Cannabis Clinical Outcomes Research Conference
Medical Cannabis and Cannabinoids. 4(2):143-146 [DOI] 10.1159/000519037. [PMID] 35224433.
2021
Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementia.
Alzheimer's research & therapy. 13(1) [DOI] 10.1186/s13195-021-00818-3. [PMID] 33883028.
2021
Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015
Drug Safety. 44(4):447-454 [DOI] 10.1007/s40264-021-01053-3. [PMID] 33683646.
2021
Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352.
Diabetes care. 44(8) [DOI] 10.2337/dci21-0024. [PMID] 34285101.
2021
Uncontrolled Pain and Risk for Depression and Behavioral Symptoms in Residents With Dementia.
Journal of the American Medical Directors Association. 22(10):2079-2086.e5 [DOI] 10.1016/j.jamda.2021.05.010. [PMID] 34089652.
2021
Use of negative controls in a prescription sequence symmetry analysis to reduce time‐varying bias
Pharmacoepidemiology and Drug Safety. 30(9):1192-1199 [DOI] 10.1002/pds.5293.
2021
Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremity amputation using real-world data.
Pharmacoepidemiology and drug safety. 30(5):644-651 [DOI] 10.1002/pds.5206. [PMID] 33606340.
2021
Utilization Patterns of Skeletal Muscle Relaxants Among Commercially Insured Adults in the United States from 2006 to 2018.
Pain medicine (Malden, Mass.). 22(10):2153-2161 [DOI] 10.1093/pm/pnab088. [PMID] 33690860.
2020
<p>Impact of the Transition from ICD–9–CM to ICD–10–CM on the Identification of Pregnancy Episodes in US Health Insurance Claims Data</p>
Clinical Epidemiology. Volume 12:1129-1138 [DOI] 10.2147/clep.s269400.
2020
<p>Medical Costs and Productivity Loss Due to Mild, Moderate, and Severe Asthma in the United States</p>
Journal of Asthma and Allergy. Volume 13:545-555 [DOI] 10.2147/jaa.s272681.
2020

Impact of the Transition from ICD–9–CM to ICD–10–CM on the Identification of Pregnancy Episodes in US Health Insurance Claims Data

Clinical Epidemiology. Volume 12:1129-1138 [DOI] 10.2147/clep.s269400.
2020

Medical Costs and Productivity Loss Due to Mild, Moderate, and Severe Asthma in the United States

Journal of Asthma and Allergy. Volume 13:545-555 [DOI] 10.2147/jaa.s272681.
2020
Age of First Use of Prescription Opioids and Prescription Opioid Non-Medical Use among Older Adolescents.
Substance use & misuse. 55(14):2420-2427 [DOI] 10.1080/10826084.2020.1823420. [PMID] 33059498.
2020
Appropriateness of Otic Quinolone Use among Privately Insured US Patients.
Otolaryngology–head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 162(1):102-107 [DOI] 10.1177/0194599819889607. [PMID] 31743076.
2020
Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry
Journal of Clinical Medicine. 9(4) [DOI] 10.3390/jcm9041166. [PMID] 32325769.
2020
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
Clinical and translational science. 13(3):473-481 [DOI] 10.1111/cts.12729. [PMID] 31758664.
2020
Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate
BMJ Quality &amp; Safety. 29(8):636-644 [DOI] 10.1136/bmjqs-2019-010098.
2020
Development and Validation of an Administrative Claims-based Measure for All-cause 30-day Risk-standardized Readmissions After Discharge From Inpatient Psychiatric Facilities
Medical Care. 58(3):225-233 [DOI] 10.1097/MLR.0000000000001275. [PMID] 32106165.
2020
Letter by Alipour Haris et al Regarding Article, “Marijuana Use Among Young Adults (18–44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor Surveillance System Survey Analysis”
Stroke. 51(5) [DOI] 10.1161/strokeaha.120.029273.
2020
Letter by Alipour Haris et al Regarding Article, “Marijuana Use Among Young Adults (18–44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor Surveillance System Survey Analysis”
Stroke. 51(5) [DOI] 10.1161/strokeaha.120.029273.
2020
Machine Learning in Drug Discovery and Development Part 1: A Primer
CPT: Pharmacometrics &amp; Systems Pharmacology. 9(3):129-142 [DOI] 10.1002/psp4.12491. [PMID] 31905263.
2020
Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials.
Pharmacoepidemiology and drug safety. 29(11):1382-1392 [DOI] 10.1002/pds.5141. [PMID] 32964514.
2020
Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
JAMA network open. 3(12) [DOI] 10.1001/jamanetworkopen.2020.29411. [PMID] 33315113.
2020
Quality of Evidence Supporting Major Psychotropic Drug‐Drug Interaction Warnings: A Systematic Literature Review
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 40(5):455-468 [DOI] 10.1002/phar.2382.
2020
Randomization versus Real-World Evidence.
The New England journal of medicine. 383(4) [DOI] 10.1056/NEJMc2020020. [PMID] 32706549.
2020
Redefining Resistant Hypertension: A Comparison of Cardiovascular Risk Associated With the 2018 Versus 2008 American Heart Association Definitions for Resistant Hypertension.
Circulation. Cardiovascular quality and outcomes. 13(2) [DOI] 10.1161/CIRCOUTCOMES.119.005979. [PMID] 32008359.
2020
Risk for Tympanic Membrane Perforation After Quinolone Ear Drops for Acute Otitis Externa.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 70(6):1103-1109 [DOI] 10.1093/cid/ciz345. [PMID] 31044229.
2020
Risk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Population-Based Cohort Study.
Clinical pharmacology and therapeutics. 108(1):81-89 [DOI] 10.1002/cpt.1807. [PMID] 32022906.
2020
Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: A retrospective cohort study
Pharmacoepidemiology and Drug Safety. 29(6):716-724 [DOI] 10.1002/pds.5017.
2020
Sex differences in peer and parental risk factors for non-medical use of prescription opioids in youth.
The American journal of drug and alcohol abuse. 46(2):203-215 [DOI] 10.1080/00952990.2019.1671436. [PMID] 31603348.
2020
Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus: A Point of Clarification.
Hypertension (Dallas, Tex. : 1979). 75(3):e2-e5 [DOI] 10.1161/HYPERTENSIONAHA.119.14447. [PMID] 32008437.
2020
Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility
Drug Safety. 43(4):329-338 [DOI] 10.1007/s40264-019-00897-0.
2020
Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee‐for‐service claims among pregnant women
Pharmacoepidemiology and Drug Safety. 29(1):30-38 [DOI] 10.1002/pds.4923.
2020
Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtract-Quantifying the misclassification of maternal drug exposure during pregnancy.
Pharmacoepidemiology and drug safety. 29(11):1414-1422 [DOI] 10.1002/pds.5126. [PMID] 32909348.
2019
Body weight, frailty, and chronic pain in older adults: a cross-sectional study.
BMC geriatrics. 19(1) [DOI] 10.1186/s12877-019-1149-4. [PMID] 31126233.
2019
Commentary on: Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence.
Annals of medicine. 51(1):97-98 [DOI] 10.1080/07853890.2019.1581941. [PMID] 30801227.
2019
Common inpatient hypoglycemia phenotypes identified from an automated electronic health record-based prediction model.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 76(3):166-174 [DOI] 10.1093/ajhp/zxy017. [PMID] 30689749.
2019
Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis.
Pharmacotherapy. 39(9):912-920 [DOI] 10.1002/phar.2311. [PMID] 31332815.
2019
Concomitant Use of Quinolones and Stimulants and the Risk of Adverse Cardiovascular Symptoms: A Retrospective Cohort Study
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 39(12):1167-1178 [DOI] 10.1002/phar.2343.
2019
Development and validation of a dynamic inpatient risk prediction model for clinically significant hypokalemia using electronic health record data.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 76(5):301-311 [DOI] 10.1093/ajhp/zxy051. [PMID] 30698650.
2019
Development and validation of an automated algorithm for identifying patients at higher risk for drug-induced acute kidney injury.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 76(10):654-666 [DOI] 10.1093/ajhp/zxz043. [PMID] 31361856.
2019
Development of a predictive model for drug-associated QT prolongation in the inpatient setting using electronic health record data.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 76(14):1059-1070 [DOI] 10.1093/ajhp/zxz100. [PMID] 31185072.
2019
Immeasurable Time Bias In Exposure to Ivacaftor.
Health affairs (Project Hope). 38(2) [DOI] 10.1377/hlthaff.2018.05175. [PMID] 30715971.
2019
Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
Pharmacotherapy. 39(11):1042-1052 [DOI] 10.1002/phar.2325. [PMID] 31479525.
2019
Impact of Schedule IV controlled substance classification on carisoprodol utilization in the United States: An interrupted time series analysis.
Drug and alcohol dependence. 202:172-177 [DOI] 10.1016/j.drugalcdep.2019.05.025. [PMID] 31352307.
2019
Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering.
Journal of clinical hypertension (Greenwich, Conn.). 21(6):825-834 [DOI] 10.1111/jch.13550. [PMID] 31066177.
2019
Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker-Induced Lower-Extremity Edema With Loop Diuretics.
JAMA network open. 2(12) [DOI] 10.1001/jamanetworkopen.2019.18425. [PMID] 31880802.
2019
Model-based standardization using an outcome model with random effects.
Statistics in medicine. 38(18):3378-3394 [DOI] 10.1002/sim.8182. [PMID] 31150151.
2019
Pain Assessments in MDS 3.0: Agreement with Vital Sign Pain Records of Nursing Home Residents.
Journal of the American Geriatrics Society. 67(11):2421-2422 [DOI] 10.1111/jgs.16122. [PMID] 31403708.
2019
Performance of the Centers for Medicare & Medicaid Services’ Opioid Overutilization Criteria for Classifying Opioid Use Disorder or Overdose.
JAMA. 321(6):609-611 [DOI] 10.1001/jama.2018.20404. [PMID] 30747958.
2019
Pharmacometrics, Physiologically Based Pharmacokinetics, Quantitative Systems Pharmacology-What’s Next?-Joining Mechanistic and Epidemiological Approaches.
CPT: pharmacometrics & systems pharmacology. 8(6):352-355 [DOI] 10.1002/psp4.12425. [PMID] 31179639.
2019
Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
Journal of Clinical Medicine. 8(7) [DOI] 10.3390/jcm8070989. [PMID] 31288397.
2019
Predicting medication-associated altered mental status in hospitalized patients: Development and validation of a risk model.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 76(13):953-963 [DOI] 10.1093/ajhp/zxz119. [PMID] 31361885.
2019
Prevalence of Maternal-Risk Factors Related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011-2015.
Pharmacotherapy. 39(10):1005-1011 [DOI] 10.1002/phar.2315. [PMID] 31361913.
2019
Psychotropic Treatment Pattern in Medicaid Pediatric Patients With Concomitant ADHD and ODD/CD.
Journal of attention disorders. 23(2):140-148 [DOI] 10.1177/1087054715596574. [PMID] 26269095.
2019
Sex differences in patterns of prescription opioid non-medical use among 10-18 year olds in the US.
Addictive behaviors. 89:163-171 [DOI] 10.1016/j.addbeh.2018.10.009. [PMID] 30316142.
2019
The International Society for Pharmacoepidemiology’s Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) – EMA Joint Big Data Task Force.
Pharmacoepidemiology and drug safety. 28(12):1640-1641 [DOI] 10.1002/pds.4911. [PMID] 31642154.
2019
Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006 to 2016: A cross-sectional study
PLOS Medicine. 16(11) [DOI] 10.1371/journal.pmed.1002941. [PMID] 31689302.
2019
Trends in prior receipt of prescription opioid or adjuvant analgesics among patients with incident opioid use disorder or opioid-related overdose from 2006 to 2016.
Drug and alcohol dependence. 204 [DOI] 10.1016/j.drugalcdep.2019.107600. [PMID] 31586806.
2019
Validation of mother‐infant linkage using Medicaid Case ID variable within the Medicaid Analytic eXtract (MAX) database
Pharmacoepidemiology and Drug Safety. 28(9):1222-1230 [DOI] 10.1002/pds.4843. [PMID] 31286606.
2019
Variation of the prevalence of pediatric polypharmacy: A scoping review.
Pharmacoepidemiology and drug safety. 28(3):275-287 [DOI] 10.1002/pds.4719. [PMID] 30724414.
2018
A Bayesian nonparametric approach to causal inference on quantiles.
Biometrics. 74(3):986-996 [DOI] 10.1111/biom.12863. [PMID] 29478267.
2018
A dynamic risk model for inpatient falls.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 75(17):1293-1303 [DOI] 10.2146/ajhp180013. [PMID] 30037814.
2018
A transdisciplinary team approach to scoping reviews: the case of pediatric polypharmacy.
BMC medical research methodology. 18(1) [DOI] 10.1186/s12874-018-0560-4. [PMID] 30286720.
2018
Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.
JAMA pediatrics. 172(2):154-160 [DOI] 10.1001/jamapediatrics.2017.3792. [PMID] 29204660.
2018
Azithromycin and Sensorineural Hearing Loss in Adults: A Retrospective Cohort Study.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 39(8):957-963 [DOI] 10.1097/MAO.0000000000001887. [PMID] 29965935.
2018
Clinical utility and perils of prescription drug monitoring program-based alert systems.
Pain. 159(4):804-805 [DOI] 10.1097/j.pain.0000000000001157. [PMID] 29557901.
2018
Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Journal of affective disorders. 238:542-546 [DOI] 10.1016/j.jad.2018.06.021. [PMID] 29936394.
2018
Defining pediatric polypharmacy: A scoping review.
PloS one. 13(11) [DOI] 10.1371/journal.pone.0208047. [PMID] 30496322.
2018
Development and validation of an automated algorithm for identifying patients at high risk for drug-induced hypoglycemia.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 75(21):1714-1728 [DOI] 10.2146/ajhp180071. [PMID] 30279185.
2018
Establishing a Multidisciplinary Framework to Study Drug-Drug Interactions of Hormonal Contraceptives: An Invitation to Collaborate.
CPT: pharmacometrics & systems pharmacology. 7(11):706-708 [DOI] 10.1002/psp4.12357. [PMID] 30260082.
2018
Internal validation of Medicaid Analytic eXtract (MAX) data capture for comprehensive managed care plan enrollees from 2007 to 2010
Pharmacoepidemiology and Drug Safety. 27(10):1067-1076 [DOI] 10.1002/pds.4365.
2018
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions. 11(2):181-191 [DOI] 10.1016/j.jcin.2017.07.022. [PMID] 29102571.
2018
Prevalence of ADHD in Publicly Insured Adults.
Journal of attention disorders. 22(2):182-190 [DOI] 10.1177/1087054717698815. [PMID] 28363250.
2018
Prevalence of and Factors Associated With Long-term Concurrent Use of Stimulants and Opioids Among Adults With Attention-Deficit/Hyperactivity Disorder.
JAMA network open. 1(4) [DOI] 10.1001/jamanetworkopen.2018.1152. [PMID] 30646105.
2018
Prevalence, Time Trends, and Utilization Patterns of Psychotropic Polypharmacy Among Pediatric Medicaid Beneficiaries, 1999-2010.
Psychiatric services (Washington, D.C.). 69(8):919-926 [DOI] 10.1176/appi.ps.201700260. [PMID] 29879872.
2018
Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population-based cohort study.
Pharmacoepidemiology and drug safety. 27(6):587-595 [DOI] 10.1002/pds.4405. [PMID] 29512263.
2018
Stimulants Do Not Increase the Risk of Seizure-Related Hospitalizations in Children with Epilepsy.
Journal of child and adolescent psychopharmacology. 28(2):111-116 [DOI] 10.1089/cap.2017.0110. [PMID] 29028437.
2018
Use of Systemic Antibiotics for Acute Otitis Externa: Impact of a Clinical Practice Guideline.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 39(9):1088-1094 [DOI] 10.1097/MAO.0000000000001955. [PMID] 30124617.
2017
Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
International journal of antimicrobial agents. 50(1):63-67 [DOI] 10.1016/j.ijantimicag.2017.02.023. [PMID] 28522340.
2017
Consistency of psychotropic drug-drug interactions listed in drug monographs.
Journal of the American Pharmacists Association : JAPhA. 57(6):698-703.e2 [DOI] 10.1016/j.japh.2017.07.008. [PMID] 28844584.
2017
Determinants of Pharmacological Treatment Initiation and Persistence in Publicly Insured Adults With Attention-Deficit/Hyperactivity Disorder.
Journal of clinical psychopharmacology. 37(5):546-554 [DOI] 10.1097/JCP.0000000000000759. [PMID] 28787373.
2017
Development and validation of a complexity score to rank hospitalized patients at risk for preventable adverse drug events.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 74(23):1970-1984 [DOI] 10.2146/ajhp160995. [PMID] 29167139.
2017
Development of a Medication Safety and Quality Survey for Small Rural Hospitals.
Journal of patient safety. 13(4):249-254 [DOI] 10.1097/PTS.0000000000000154. [PMID] 25719815.
2017
Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers.
The Journal of clinical psychiatry. 78(7):e744-e781 [DOI] 10.4088/JCP.16m10884. [PMID] 28686819.
2017
Identifying and characterizing preventable adverse drug events for prioritizing pharmacist intervention in hospitals.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 74(21):1774-1783 [DOI] 10.2146/ajhp160387. [PMID] 29070499.
2017
Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics. 18(5):421-426 [DOI] 10.2217/pgs-2017-0028. [PMID] 28346068.
2017
Measurement of selected preventable adverse drug events in electronic health records: Toward developing a complexity score.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 74(22):1865-1877 [DOI] 10.2146/ajhp160911. [PMID] 29118045.
2017
Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics.
Journal of child and adolescent psychopharmacology. 27(9):833-839 [DOI] 10.1089/cap.2017.0006. [PMID] 28708433.
2017
Prevalence of Psychotherapy Surrounding Initiation of Psychotropic Polypharmacy in the Medicaid-Insured Population, 1999-2010.
Psychiatric services (Washington, D.C.). 68(11):1120-1126 [DOI] 10.1176/appi.ps.201600511. [PMID] 28669287.
2017
Quinolone Ear Drops After Tympanostomy Tubes and the Risk of Eardrum Perforation: A Retrospective Cohort Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 64(8):1052-1058 [DOI] 10.1093/cid/cix032. [PMID] 28329128.
2017
Trends in Antiepileptic Drug Use in Children and Adolescents With Epilepsy
Pediatric Neurology. 74:32-40 [DOI] 10.1016/j.pediatrneurol.2017.05.016.
2017
Trends of Neonatal Abstinence Syndrome Epidemic and Maternal Risk Factors in Florida.
Pharmacotherapy. 37(7):806-813 [DOI] 10.1002/phar.1947. [PMID] 28500694.
2016
Development of a refill pattern method to measure polypharmacy in administrative claims databases.
Pharmacoepidemiology and drug safety. 25(12):1407-1413 [DOI] 10.1002/pds.4082. [PMID] 27528378.
2016
Epidemiology of Persistent Tympanic Membrane Perforations Subsequent to Tympanostomy Tubes Assessed With Real World Data.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 37(9):1376-80 [DOI] 10.1097/MAO.0000000000001195. [PMID] 27636392.
2016
Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.
Pediatrics. 137(5) [DOI] 10.1542/peds.2015-3199. [PMID] 27244795.
2016
Sequential BART for imputation of missing covariates.
Biostatistics (Oxford, England). 17(3):589-602 [DOI] 10.1093/biostatistics/kxw009. [PMID] 26980459.
2016
Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides.
Pharmacoepidemiology and drug safety. 25(6):678-86 [DOI] 10.1002/pds.3894. [PMID] 26597624.
2016
Utilization of Alcohol Treatment Among HIV-Positive Women with Hazardous Drinking.
Journal of substance abuse treatment. 64:55-61 [DOI] 10.1016/j.jsat.2016.01.011. [PMID] 26961420.
2015
Application of multicategory exposure marginal structural models to investigate the association between long-acting beta-agonists and prescribing of oral corticosteroids for asthma exacerbations in the Clinical Practice Research Datalink.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 18(2):260-70 [DOI] 10.1016/j.jval.2014.11.007. [PMID] 25773561.
2015
Clinical and Sociodemographic Factors Associated With Attention-Deficit/Hyperactivity Disorder in Patients With Cystic Fibrosis.
Psychosomatics. 56(5):495-503 [DOI] 10.1016/j.psym.2014.09.001. [PMID] 25620567.
2015
Patient understanding of drug risks: an evaluation of medication guide assessments.
Pharmacoepidemiology and drug safety. 24(5):518-25 [DOI] 10.1002/pds.3762. [PMID] 25808393.
2014
Anti-diabetic drug utilization of pregnant diabetic women in us managed care.
BMC pregnancy and childbirth. 14 [DOI] 10.1186/1471-2393-14-28. [PMID] 24438493.
2014
Authors’ responses in response to the letter from Ambrose.
Pediatrics. 134(6):e1782-3 [DOI] 10.1542/peds.2014-2901C. [PMID] 25452650.
2014
Comparison of Rates of Prescribing Oral Corticosteroids for Asthma Exacerbations Between Step-Down Therapy Approaches Among Initiators of Inhaled Corticosteroids and Long-Acting Beta-Agonist Combination Therapy
. 133(2, S)
2014
Development of a Novel Approach To Assess Psychotropic Polypharmacy in Administrative Databases
Pharmacoepidemiology and Drug Safety. 23(1, SI)
2014
Diabetogenic Effects of Atypical Antipsychotics Exploration of Measurement Bias
Pharmacoepidemiology and Drug Safety. 23(1, SI):142-143
2014
Epidemiology of Pre-Existing Diabetes in Pregnancy From 2000-2006 Among Medicaid Patients in 29 Us States
Pharmacoepidemiology and Drug Safety. 23(1, SI)
2014
Measurement Bias in Billing Data – a Simulation Study
Pharmacoepidemiology and Drug Safety. 23(1, SI):149-150
2014
Methods to estimate gestational age can significantly affect study results–reply.
JAMA pediatrics. 168(4):388-9 [DOI] 10.1001/jamapediatrics.2013.5178. [PMID] 24710586.
2014
Misclassification in assessment of diabetogenic risk using electronic health records.
Pharmacoepidemiology and drug safety. 23(8):875-81 [DOI] 10.1002/pds.3656. [PMID] 24923707.
2014
Negative Results Do Not Imply Absence of Ototoxicity with Middle Ear Application of Neomycin.
Otolaryngology–head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 151(2) [DOI] 10.1177/0194599814537033. [PMID] 25057051.
2014
Pharmacotherapy for incident attention-deficit/hyperactivity disorder: practice patterns and quality metrics.
Current medical research and opinion. 30(8):1687-99 [DOI] 10.1185/03007995.2014.905461. [PMID] 24635013.
2014
Predicting Linkage Within a Validated Algorithm That Identifies Mother-Infant Pairs Within the Medicaid Analytic Extract (Max) Database
Pharmacoepidemiology and Drug Safety. 23(1, SI)
2014
Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.
The international journal of neuropsychopharmacology. 17(7):1095-105 [DOI] 10.1017/S1461145712001320. [PMID] 23673334.
2014
Psychotropic drug utilization in children with concurrent attention-deficit/hyperactivity disorder and anxiety.
Journal of anxiety disorders. 28(6):530-6 [DOI] 10.1016/j.janxdis.2014.06.005. [PMID] 24981018.
2014
RE: Drug risk assessment and data reuse.
Pharmacoepidemiology and drug safety. 23(1):109-10 [DOI] 10.1002/pds.3525. [PMID] 24395550.
2014
Stimulant Effectiveness On Driving Citations and Crashes of Children With Adhd
Pharmacoepidemiology and Drug Safety. 23(1, SI):151-152
2014
Utilization Pattern of Phosphodiesterase Type 5 (Pde5) Inhibitors for Erectile Dysfunction Among Commercially Insured Adults in the United States
Pharmacoepidemiology and Drug Safety. 23(1, SI):85-86
2013
Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study.
Journal of the American Heart Association. 2(3) [DOI] 10.1161/JAHA.113.000125. [PMID] 23752710.
2013
Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.
JAMA pediatrics. 167(12):1118-24 [DOI] 10.1001/jamapediatrics.2013.2636. [PMID] 24126903.
2013
Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study.
Atherosclerosis. 229(2):310-6 [DOI] 10.1016/j.atherosclerosis.2013.05.002. [PMID] 23880181.
2013
Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.
Current psychiatry reports. 15(8) [DOI] 10.1007/s11920-013-0379-y. [PMID] 23913135.
2013
Confounding’s Ugly Little Sister: Measurement Bias in Pharmacoepidemiology
Pharmacoepidemiology and Drug Safety. 22(1, SI):369-370
2013
Distribution and Development of Co-Morbidities in Pediatric Patients With Adhd
Pharmacoepidemiology and Drug Safety. 22(1, SI):341-342
2013
Inclusion of Variables Associated With Exposure But Not Outcome Can Compromise Propensity Score-Based Adjustments – Examination of a Real-Life Example in Pediatric Psychopharmacology
Pharmacoepidemiology and Drug Safety. 22(1, SI)
2013
Long-Acting Beta-Agonists and Asthma Exacerbations Requiring Short Courses of Oral Corticosteroids: a Multi-Category Exposure Marginal Structural Models Analysis
Value in Health. 16
2013
Misclassification in Assessment of Diabetogenic Risk Using Laboratory-Enhanced Claims Data
Pharmacoepidemiology and Drug Safety. 22(1, SI):3-4
2013
Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
Pediatric pulmonology. 48(9):874-84 [DOI] 10.1002/ppul.22711. [PMID] 23139089.
2013
Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications.
Current psychiatry reports. 15(8) [DOI] 10.1007/s11920-013-0382-3. [PMID] 23881713.
2013
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.
Pharmacoepidemiology and drug safety. 22(10):1036-45 [DOI] 10.1002/pds.3478. [PMID] 23922322.
2013
Response to Letter to the editor regarding Sensorineural hearing loss associated with neomycin eardrops and nonintact tympanic membranes.
Otolaryngology–head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 148(6):1061-2 [DOI] 10.1177/0194599813486085. [PMID] 23690083.
2013
Risk of Suicide and Suicide Attempt Associated With Atomoxetine Compared To Central Nervous System Stimulant Treatment
Pharmacoepidemiology and Drug Safety. 22(1, SI):175-176
2013
Sensorineural hearing loss associated with neomycin eardrops and nonintact tympanic membranes.
Otolaryngology–head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 148(2):277-83 [DOI] 10.1177/0194599812471499. [PMID] 23264116.
2013
Validity of laboratory-based surveillance for detection of respiratory syncytial virus seasons.
American journal of epidemiology. 177(8):841-51 [DOI] 10.1093/aje/kws304. [PMID] 23479344.
2012
ADHD treatment–supply or demand?
Pharmacoepidemiology and drug safety. 21(4):450-1 [DOI] 10.1002/pds.3192. [PMID] 22290762.
2012
Aminoglycoside Eardrops and Risk of Sensorineural Hearing Loss in Children With Non-Intact Tympanic Membranes
Pharmacoepidemiology and Drug Safety. 21:133-134
2012
An algorithm to identify preterm infants in administrative claims data.
Pharmacoepidemiology and drug safety. 21(6):640-50 [DOI] 10.1002/pds.3264. [PMID] 22504840.
2012
Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.
BMJ (Clinical research ed.). 345 [DOI] 10.1136/bmj.e4627. [PMID] 22809800.
2012
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy.
BMC medical research methodology. 12 [DOI] 10.1186/1471-2288-12-119. [PMID] 22866767.
2012
Determinants of Atomoxetine and Central Nervous System Stimulant Treatment Initiation
Pharmacoepidemiology and Drug Safety. 21
2012
Deterministic Linkage Between Cystic Fibrosis Patient Registry Data and Medicaid Analytical Extract Data
Pediatric Pulmonology. 47:379-380
2012
Deterministic Linkage Between Cystic Fibrosis Patient Registry Data To Medicaid Analytical Extract Data
Pharmacoepidemiology and Drug Safety. 21:396-397
2012
Drug Utilization Among Pregnant Diabetic Women in Us Managed Care
Pharmacoepidemiology and Drug Safety. 21
2012
Drug Utilization Patterns for Routine Therapies in Patients With Cystic Fibrosis
Pharmacoepidemiology and Drug Safety. 21
2012
Effectiveness of Palivizumab in Respiratory Syncytial Virus Prophylaxis in Children With Cystic Fibrosis
Pharmacoepidemiology and Drug Safety. 21
2012
Effectiveness of palivizumab prophylaxis in infants and children in Florida.
Pharmacoepidemiology and drug safety. 21(1):53-60 [DOI] 10.1002/pds.2246. [PMID] 21919115.
2012
Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid-Reply.
Archives of pediatrics & adolescent medicine. 166(10):968-70 [DOI] 10.1001/archpediatrics.2012.1594. [PMID] 23753905.
2012
Ototopical neomycin exposure in children with nonintact tympanic membranes.
The Laryngoscope. 122(11):2529-32 [DOI] 10.1002/lary.23554. [PMID] 22965584.
2012
Polypharmacy in attention deficit hyperactivity disorder treatment: current status, challenges and next steps.
Current psychiatry reports. 14(5):447-9 [DOI] 10.1007/s11920-012-0295-6. [PMID] 22684300.
2012
Psychotropic Drug Utilization in Children With Concomitant Adhd and Anxiety
Pharmacoepidemiology and Drug Safety. 21
2012
Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
Journal of the American Academy of Child and Adolescent Psychiatry. 51(2):147-56 [DOI] 10.1016/j.jaac.2011.11.008. [PMID] 22265361.
2012
Trends in Use of Benzodiazepines, Opioids, Tramadol, and Z-Drugs From 1998 To 2008 in a Managed Care Population
Pharmacoepidemiology and Drug Safety. 21
2012
Trends in Utilization of Medications With Adverse Metabolic Effects in a Managed Care Population Between 1999 and 2008
Pharmacoepidemiology and Drug Safety. 21
2012
Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use.
Evidence-based mental health. 15(2) [DOI] 10.1136/ebmental-2011-100514. [PMID] 22334580.
2012
Utilization of Antiepileptic Drugs in Florida Medicaid Women With Epilepsy of Childbearing Age
Pharmacoepidemiology and Drug Safety. 21
2011
[Endovascular brachytherapy (EVBT) with Rhenium-188 for restenosis prophylaxis after angioplasty of infrainguinal lesions: early experience].
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 183(8):735-42 [DOI] 10.1055/s-0031-1273446. [PMID] 21800265.
2011
Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
The Annals of pharmacotherapy. 45(7-8):861-8 [DOI] 10.1345/aph.1Q161. [PMID] 21712506.
2011
Adhd Youths’ Career in Psychotropic Treatment
Pharmacoepidemiology and Drug Safety. 20
2011
Age-Dependent Effectiveness of Rsv Immunoprophylaxis
Pharmacoepidemiology and Drug Safety. 20
2011
An in-depth analysis of medication errors in hospitalized patients with HIV.
The Annals of pharmacotherapy. 45(4):459-68 [DOI] 10.1345/aph.1P599. [PMID] 21487084.
2011
Appropriateness of Age Thresholds for Palivizumab Prophylaxis in Preterm Infants
Pharmacoepidemiology and Drug Safety. 20
2011
Association of Cesarean Section Delivery Among Pregnant Women With Diabetes.
American Journal of Epidemiology. 173
2011
Atomoxetine Utilization in Youths With Attention Deficit/Hyperactivity Disorder in 29 Medicaid States
Pharmacoepidemiology and Drug Safety. 20
2011
Comparing Pulmonary-Related Outcomes for Newborn-Screened Versus Conventional-Diagnosed Infants With Cystic Fibrosis
Pharmacoepidemiology and Drug Safety. 20
2011
Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Archives of pediatrics & adolescent medicine. 165(6):498-505 [DOI] 10.1001/archpediatrics.2010.298. [PMID] 21300647.
2011
Do Physicians Need Both Rosiglitazone and Pioglitazone?
Pharmacoepidemiology and Drug Safety. 20
2011
Generalizability of Risk Evaluation and Mitigation Strategies (Rems) Effectiveness Evaluations
Pharmacoepidemiology and Drug Safety. 20
2011
Health Related Quality of Life as Confounder in Observational Studies for Localized Prostate Cancer
Pharmacoepidemiology and Drug Safety. 20
2011
Hip Osteoarthritis MRI Scoring System (HOAMS): reliability and associations with radiographic and clinical findings.
Osteoarthritis and cartilage. 19(8):946-62 [DOI] 10.1016/j.joca.2011.04.003. [PMID] 21550411.
2011
Intensive glucose lowering and cardiovascular outcomes.
The New England journal of medicine. 364(23) [DOI] 10.1056/NEJMc1103669. [PMID] 21651404.
2011
Patient counseling practices in U.S. pharmacies: effects of having pharmacists hand the medication to the patient and state regulations on pharmacist counseling.
Journal of the American Pharmacists Association : JAPhA. 51(4):527-34 [DOI] 10.1331/JAPhA.2011.10012. [PMID] 21752776.
2011
Rosiglitazone and the risk of adverse cardiovascular outcomes.
Clinical pharmacology and therapeutics. 89(6):776-8 [DOI] 10.1038/clpt.2011.43. [PMID] 21593751.
2011
Utilization of Atomoxetine and Other Pharmacotherapy in Youths With Attention Deficit/Hyperactivity Disorder in Medicaid Patients in 29 Us States
American Journal of Epidemiology. 173
2010
Comparison of Rsv Seasonality in Four States
American Journal of Epidemiology. 171
2010
Evaluation of consumer medication information dispensed in retail pharmacies.
Archives of internal medicine. 170(15):1317-24 [DOI] 10.1001/archinternmed.2010.263. [PMID] 20696955.
2010
Latitude as a Factor in Rsv Epidemiology in Florida
American Journal of Epidemiology. 171
2010
Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida.
The Journal of pediatrics. 156(6):953-959.e1 [DOI] 10.1016/j.jpeds.2009.12.016. [PMID] 20223478.
2010
Perioperative medication errors in otolaryngology.
The Laryngoscope. 120(6):1214-9 [DOI] 10.1002/lary.20922. [PMID] 20513042.
2010
Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.
Pharmacoepidemiology and drug safety. 19(5):457-64 [DOI] 10.1002/pds.1931. [PMID] 20232490.
2010
Projecting the effect of nesiritide on dialysis and hospital mortality in cardiac surgery patients.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 13(5):643-8 [DOI] 10.1111/j.1524-4733.2010.00710.x. [PMID] 20345547.
2010
Reply To Discussion of `Empirical Vs Natural Weighting in Random Effects Meta-Analysis’
Statistics in Medicine. 29(12):1272-1281 [DOI] 10.1002/sim.3842.
2010
Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxis.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 13(5) [DOI] 10.1111/j.1524-4733.2010.00723.x. [PMID] 20412545.
2010
Topical dexamethasone and tympanic membrane perforation healing in otitis media: a short-term study.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 31(3):519-23 [DOI] 10.1097/MAO.0b013e3181ca85cc. [PMID] 20010446.
2009
Atomoxetine (Ato) Use and Central Nervous System Stimulants (Cnss) Use During Physician-Office Visit for Attention Deficit/Hyperactivity Disorders (Adhd) After the Discussion On Ato Related Suicidal Risk
Pharmacoepidemiology and Drug Safety. 18
2009
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
Pediatrics. 124(1):e75-80 [DOI] 10.1542/peds.2008-3138. [PMID] 19564272.
2009
Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis With Palivizumab From the Perspective of a Southern Us Medicaid Agency
Value in Health. 12(7):A301-A302 [DOI] 10.1016/S1098-3015(10)74479-X.
2009
Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder.
Journal of child and adolescent psychopharmacology. 19(2):187-95 [DOI] 10.1089/cap.2008.096. [PMID] 19364296.
2009
Effects of Preexisting Cardiovascular Risk Factors On Initiation of Stimulants in Adults Newly Diagnosed With Adhd
Pharmacoepidemiology and Drug Safety. 18
2009
Interpreting Data About Prolongation of the Q-Tc Interval Induced By Amiodarone and Haloperidol
American Journal of Health-System Pharmacy. 66 [DOI] 10.2146/ajhp090169.
2009
Patient Counseling Efforts in Us Community Pharmacies: Associations To Pharmacy and Personnel Attributes
Pharmacoepidemiology and Drug Safety. 18
2009
Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery.
The Journal of thoracic and cardiovascular surgery. 138(4):959-64 [DOI] 10.1016/j.jtcvs.2009.05.014. [PMID] 19660420.
2009
Seasonal Versus Needs-Based Immunization Schedules-the Example of Rsv
Value in Health. 12(7) [DOI] 10.1016/S1098-3015(10)74509-5.
2009
Usefulness of Consumer Medication Information (Cmi)
Pharmacoepidemiology and Drug Safety. 18
2009
Validation of the National Respiratory and Enteric Virus Surveillance System for the Detection of Respiratory Syncytial Virus Seasons
Pharmacoepidemiology and Drug Safety. 18
2008
A tool kit for practice-based research.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 65(17) [DOI] 10.2146/ajhp080204. [PMID] 18714105.
2008
An evaluation of the effects of gatifloxacin on glucose homeostasis.
Pharmacy world & science : PWS. 30(5):544-9 [DOI] 10.1007/s11096-008-9205-8. [PMID] 18297409.
2008
Effect of an academic detailing intervention on the utilization rate of cyclooxygenase-2 inhibitors in the elderly.
The Annals of pharmacotherapy. 42(6):749-56 [DOI] 10.1345/aph.1K537. [PMID] 18430793.
2008
Effects of concomitant amiodarone and haloperidol on Q-Tc interval prolongation.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 65(23):2232-6 [DOI] 10.2146/ajhp080039. [PMID] 19020191.
2008
Fixed Effects Models May Bias Meta-Analytic Summary Estimates
Pharmacoepidemiology and Drug Safety. 17
2008
Nesiritide following maze and mitral valve surgery.
Journal of cardiac surgery. 23(5):431-6 [DOI] 10.1111/j.1540-8191.2007.00552.x. [PMID] 18928481.
2008
Off-Label Prescribing of Anticonvulsant Drugs – National Pattern Between 1992-2005
Pharmacoepidemiology and Drug Safety. 17
2008
Palivizumab Utilization and Compliance With Recommendations in Florida
Pharmacoepidemiology and Drug Safety. 17
2008
Predicted Impact of Nesiritide On Dialysis and All-Cause Hospital Mortality in Cardiac Surgery Patients By Demonstrated Post-Operative Gfr Change
Pharmacoepidemiology and Drug Safety. 17:S241-S242
2008
Predicted Impact of Nesiritide On Dialysis and All-Cause Hospital Mortality in Patients Undergoing Cardiac Surgery By Demonstrated Improvement in Post-Operative Glomerular Filtration Rate
Journal of the American College of Cardiology. 51
2008
Response to respiratory synctial virus.
Southern medical journal. 101(2):212-3; author reply 213 [DOI] 10.1097/SMJ.0b013e3181611d5f. [PMID] 18364631.
2008
Risk of Tendon Rupture After Quinolone Use in a Us Military Population
Pharmacoepidemiology and Drug Safety. 17
2008
Role of Age in Respiratory Syncycial Virus Infection Risk – Recommendations for Palivizumab Utilization
Pharmacoepidemiology and Drug Safety. 17
2008
Treatment Persistence Among Youths Newly Diagnosed With Attention-Deficit/Hyperactivity Disorder (Adhd)
Pharmacoepidemiology and Drug Safety. 17
2008
Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
The Annals of pharmacotherapy. 42(1):24-31 [PMID] 18042808.
2008
Validity and reliability of measurement instruments used in research.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 65(23):2276-84 [DOI] 10.2146/ajhp070364. [PMID] 19020196.
2007
Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Pediatrics. 120(6):e1494-501 [PMID] 18055666.
2007
Efficacy and safety of oral phenylephrine: systematic review and meta-analysis.
The Annals of pharmacotherapy. 41(3):381-90 [PMID] 17264159.
2007
Planning for pharmacy health information technology in critical access hospitals.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 64(3):315-21 [PMID] 17244881.
2007
Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care.
The Annals of pharmacotherapy. 41(9):1411-26 [PMID] 17666582.
2006
Automated medication error studies with audit supplementation were effectively designed and analyzed by time series.
Journal of clinical epidemiology. 59(9):957-63 [PMID] 16895819.
2006
Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery.
Clinical cardiology. 29(1):18-24 [PMID] 16477773.
2006
Medication safety infrastructure in critical-access hospitals in Florida.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 63(5):442-50 [PMID] 16484518.
2006
Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.
Pharmacotherapy. 26(1):34-43 [PMID] 16509026.
2005
Causes of hyperglycemia and hypoglycemia in adult inpatients.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 62(7):714-9 [PMID] 15790798.
2005
Pharmacy-specific quality indicators for asthma therapy.
Research in social & administrative pharmacy : RSAP. 1(3):430-45 [PMID] 17138488.
2004
Nature and causes of clinically significant medication errors in a tertiary care hospital.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 61(18):1908-16 [PMID] 15487880.
2003
Nature of preventable adverse drug events in hospitals: a literature review.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 60(17):1750-9 [PMID] 14503111.
2002
Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reaction reports.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 59(18):1742-9 [PMID] 12298112.
2002
Manufacturer warnings of system-related medication errors.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 59(11):1110-2 [PMID] 12063898.
2002
Preventable drug-related hospital admissions.
The Annals of pharmacotherapy. 36(7-8):1238-48 [PMID] 12086559.
2001
Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven European countries.
Drugs & aging. 18(1):63-77 [PMID] 11232739.

Grants

Sep 2022 ACTIVE
Evaluation of Emerging Infections during Pregnancy and their Prevention and Treatment using Enhanced and Diverse Mother-Baby Cohorts
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2022 ACTIVE
Building Equity Improvement into Quality Improvement in the use of New Glucose-lowering Drugs (GLDs) through Individualized Drug Value Assessment in People with Diabetes
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
Dec 2021 ACTIVE
Merck Graduate Program Work Plan #2
Role: Principal Investigator
Funding: MERCK AND COMPANY INC
Sep 2021 ACTIVE
Teratogenic Risk Impact and Mitigation (TRIM): An Evidence-based Decision Framework
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
May 2021 – Oct 2022
Preventing the Calcium Channel Blocker Lower Extremity Edema Loop Diuretic Prescribing Cascade in Older Adults
Role: Other
Funding: NATL INST OF HLTH NIA
Dec 2020 – Sep 2022
Sentinel 2014: TreeScan in Pregnancy Maternal Outcomes
Role: Principal Investigator
Funding: HARVARD PILGRIM HEALTHCARE via US FOOD AND DRUG ADMN
Jul 2020 ACTIVE
Precision antiplatelet therapy after percutaneous coronary intervention
Role: Co-Investigator
Funding: NATL INST OF HLTH NHLBI
May 2020 – Sep 2022
Epidemiology and cost of RSV infections in infants and toddlers
Role: Principal Investigator
Funding: MERCK AND COMPANY INC
Dec 2019 – Dec 2021
BD&L Discovery Transactions Work Plan
Role: Principal Investigator
Funding: MERCK AND COMPANY INC
Jul 2019 – Jun 2021
Together: Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Jul 2019 – Dec 2020
Consortium for Medical Marijuana Clinical Outcomes Research
Role: Principal Investigator
Funding: STATE UNIVERSITY SYSTEM OF FLORIDA via FL LEGISLATURE
May 2019 – Sep 2019
Observational External Comparator Cohorts as Controls for Long-Term Uncontrolled Extensions to RCTs
Role: Principal Investigator
Funding: INTL SOC FOR PHARMACOEPIDEMIOLOGY
May 2019 – Jan 2022
Developing a Real-Time Trajectory Tool to Identify Potentially Unsafe Concurrent Opioid and Benzodiazepine Use among Older Adults
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2018 – Feb 2019
Inpatient Psychiatric Facility Outcome & Process Amendment 2 – Year 5 Option Year 4 (September 30, 2018 to February 15, 2019)
Role: Principal Investigator
Funding: HEALTH SERVICES ADVISORY GROUP via CTRS FOR MEDICARE & MEDICAID SERVICES
Sep 2018 – Mar 2021
Safety of Gadolinium-Enhanced MRI Exposure During Pregnancy on Adverse Fetal Outcomes
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Jul 2018 ACTIVE
Advancing Personalized Hypertension Care through Big Data Science
Role: Other
Funding: NATL INST OF HLTH NHLBI
May 2018 ACTIVE
Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma (MATCH)
Role: Co-Investigator
Funding: NEMOURS CHILDRENS CLINIC via NATL INST OF HLTH NHLBI
May 2018 ACTIVE
Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
Role: Other
Funding: NATL INST OF HLTH NIDA
Nov 2017 ACTIVE
Application of physiologically-based pharmacokinetic models to inform dosing recommendations for hormonal contraceptives co-administered with other medications
Role: Co-Investigator
Funding: GATES FOU, BILL & MELINDA
Sep 2017 – Sep 2018
HHSM-500-2013-13007I, Task Order # HHSM-500-T0004, Inpatient Psychiatric Facility Outcome and Process Measure Development & Maintenance_Task 2.1
Role: Principal Investigator
Funding: HEALTH SERVICES ADVISORY GROUP via CTRS FOR MEDICARE & MEDICAID SERVICES
Sep 2017 – Mar 2021
Task Order: Developing the Capability of Using National Medicaid data for FDA Post-Marketing Surveillance to Assess Medication Safety During Pregnancy
Role: Principal Investigator
Funding: BRIGHAM AND WOMENS HOSPITAL via US FOOD AND DRUG ADMN
Aug 2017 – May 2022
Pharmacological Management of Pain in Alzheimer's Disease and Related Dementia
Role: Other
Funding: NATL INST OF HLTH NIA
Feb 2017 – Feb 2017
TRAVEL REIMBURSEMENT AGREEMENT
Role: Principal Investigator
Funding: HARVARD PILGRIM HEALTHCARE via US FOOD AND DRUG ADMN
Sep 2016 – Sep 2020
The Child Health Quality (CHeQ) Partnership Program
Role: Co-Investigator
Funding: AGCY HEALTHCARE RES AND QUALITY
Jan 2016 – Jan 2017
evaluating changes in order sets for impatient pain
Role: Principal Investigator
Funding: *SHANDS TEACHING HOSPITAL HEALTHCARE
Sep 2015 – Jan 2018
Real-time risk stratification for hypo- or hyperglycemia
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Sep 2015 – Sep 2017
inpatient psychiatric facility outcome & process measure
Role: Principal Investigator
Funding: HEALTH SERVICES ADVISORY GROUP via CTRS FOR MEDICARE & MEDICAID SERVICES
Sep 2014 – Sep 2015
MIDS-141193: Inpatient Psychiatric Facility Outcome & Process Measure Development and Maintenance
Role: Principal Investigator
Funding: HEALTH SERVICES ADVISORY GROUP via CTRS FOR MEDICARE & MEDICAID SERVICES
Jul 2013 – Jun 2016
Development and Validation of a Complexity Score to Identify Hospitalized Patients at High Risk for Preventable Adverse Events
Role: Principal Investigator
Funding: AMER SOC HLTH SYS PHARM FOU

Education

Post-doctoral fellowship
1999-2000 · University of Florida
Ph.D.
1999 · Humboldt University, Pharmacoepidemiology
Pharmacy
1990 · Friedrich Wilhelm University

Contact Details

Phones:
Business:
(352) 273-6258
Emails:
Business:
almut@ufl.edu
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610
Business Street:
1225 CENTER DR
HPNP 3336
GAINESVILLE FL 326103007

recent news

Dr. Almut Winterstein elected to the Academy of Science, Engineering and Medicine of Florida

Fourteen members of the class of 2022 were officially inducted at the ASEMFL Annual Meeting in Orlando on Nov. 5.

UF Health researchers find quinolone ear drops associated with tendon ruptures

Research by Patrick Antonelli, M.D., and Almut Winterstein, Ph.D., shows quinolone ear drops used to treat infection increase the risk of tendon ruptures.

Dr. Winterstein honored with special ISPE award for COVID-19 pandemic contributions

Dr. Winterstein was one of nine ISPE members honored with the award at the 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Copenhagen, Denmark.

From Florida Podcast: What is Florida’s medical marijuana research consortium studying – and what has it found so far?

Almut Winterstein, Ph.D., joined the From Florida podcast with Nicci Brown to discuss medical marijuana research.